Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

CNTA
Centessa Pharmaceuticals plc
stock NASDAQ ADR

At Close
Nov 7, 2025 3:59:54 PM EST
22.09USD-2.794%(-0.64)1,710,930
0.00Bid   0.00Ask   0.00Spread
Pre-market
Nov 5, 2025 9:28:30 AM EST
18.31USD-19.446%(-4.42)0
After-hours
Nov 6, 2025 4:00:30 PM EST
22.84USD+0.462%(+0.11)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Dec 14, 2021
08:22AM EST  The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks   Benzinga
07:39AM EST  Centessa Pharma Begins Global Phase 3 ACTION Study Of Lixivaptan In Autosomal Dominant Polycystic Kidney Disease   RTTNews
07:37AM EST  Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study Of Lixivaptan In Autosomal Dominant Polycystic Kidney Disease   Benzinga
07:30AM EST  ~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~~W0:   GlobeNewswire Inc
Dec 13, 2021
04:16PM EST  Centessa Pharma To Be Added To NASDAQ Biotech Index, Effective Dec. 20, 2021   Benzinga
04:15PM EST  Centessa Pharmaceuticals Announces Addition to NASDAQ   GlobeNewswire Inc
Nov 15, 2021
10:56AM EST  Centessa Pharmaceuticals Q3 EPS $(0.45)   Benzinga
07:00AM EST  ~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~~W0:   GlobeNewswire Inc
Nov 1, 2021
03:23PM EDT  Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide   Benzinga
12:14PM EDT  Mid-Day Market Update: Dow Rises 50 Points; ANI Pharmaceuticals Shares Jump   Benzinga
10:35AM EDT  Mid-Morning Market Update: Markets Mixed; PG&E Earnings Miss views   Benzinga
07:34AM EDT  Centessa Pharmaceuticals Demonstrates Proof-Of-Mechanism From First Three PiMZ Subjects Dosed In Part B Of Phase 1 Study Evaluating ZF874   Benzinga
07:30AM EDT  ~ First demonstration that a pharmacological chaperone can provide sufficient functional Z-A1AT increases to potentially achieve greater than 11 micromolar levels in individuals with PiZZ genotype ~~W0:   GlobeNewswire Inc
Oct 18, 2021
08:05AM EDT  Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, And Schrdinger Announce Collaboration To Discover Novel Orexin Receptor Agonists   Benzinga
08:00AM EDT  00C2Discovery efforts will focus on small molecules with differentiated clinical profiles to harness the broad potential of orexin agonism across different indications~~W0:   GlobeNewswire Inc
08:00AM EDT  Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrdinger Announce Collaboration to Discover Novel Orexin Receptor Agonists   Business Wire
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
08:00AM EDT  Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading   GlobeNewswire Inc
Oct 4, 2021
08:15AM EDT  Centessa Pharmaceuticals Announces $300M Financing Agreement With Oberland Capital   Benzinga
08:00AM EDT  Centessa Pharmaceuticals plc (Centessa or Company) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that it has entered into a$300 millionfinancing agreement withfunds managed by Oberland Capital Management LLC (Oberland Capital).   GlobeNewswire Inc
Oct 1, 2021
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 28, 2021
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 9, 2021
07:39AM EDT  Centessa Pharmaceuticals Announces Data From Proof-of-Concept Study Of SerpinPC In Severe Hemophilia A And B Patients Not On Prophylaxis   Benzinga
07:30AM EDT  ~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~~W0:   GlobeNewswire Inc
Sep 1, 2021
04:15PM EDT  Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021, beginning at 5:00 p.m. Eastern Time.   GlobeNewswire Inc
Aug 16, 2021
07:11AM EDT  Centessa Pharmaceuticals Q2 EPS $(0.65)   Benzinga
07:00AM EDT  ~ Successful completion of an initial public offering of American Depositary Shares raising gross proceeds of $379.5 million to help advance portfolio of 16 clinical and preclinical programs ~~W0:   GlobeNewswire Inc
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jun 23, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2021   Benzinga
07:27AM EDT  Morgan Stanley Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $37   Benzinga
Jun 22, 2021
06:16AM EDT  Goldman Sachs Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $42   Benzinga
06:13AM EDT  Morgan Stanley Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $37   Benzinga
05:25AM EDT  Jefferies Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $35   Benzinga
Jun 15, 2021
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 7, 2021
04:15PM EDT  Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an analyst-led fireside chat at the Goldman Sachs 42ndAnnual Global Healthcare Conference on Tuesday, June 8, 2021, beginning at 5:30 p.m. Eastern Time.   GlobeNewswire Inc
Jun 4, 2021
04:15PM EDT  Centessa Announces Closing of Initial Public Offering and Full   GlobeNewswire Inc
Jun 3, 2021
08:23AM EDT  The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout   Benzinga
May 27, 2021
11:02PM EDT  Centessa Prices IPO Of 16.50 Mln ADSs At $20.00/ADS   RTTNews
10:49PM EDT  Centessa Announces Pricing of Initial Public Offering   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC